HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1

BACKGROUND: Intrahepatic cholangiocarcinoma (ICC) is a highly mortal malignancy with limited therapeutic options. Immunotherapies targeting PD-1/PD-L1 pathway represent a promising treatment for ICC. However, PD-L1 expression and microsatellite instability are not common in ICC. This study aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Jing, Chu-Yu, Fu, Yi-Peng, Yi, Yong, Zhang, Mei-Xia, Zheng, Su-Su, Huang, Jin-Long, Gan, Wei, Xu, Xin, Lin, Jia-Jia, Zhang, Juan, Qiu, Shuang-Jian, Zhang, Bo-Heng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6421676/
https://www.ncbi.nlm.nih.gov/pubmed/30885276
http://dx.doi.org/10.1186/s40425-019-0554-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6421676/
https://www.ncbi.nlm.nih.gov/pubmed/30885276
http://dx.doi.org/10.1186/s40425-019-0554-8

Ejemplares similares